Total Payments
$60,308
2024 Payments
$6,781
Companies
66
Transactions
388
Medicare Patients
19,886
Medicare Billing
$3.8M
Payment Breakdown by Category
Other$32,792 (54.4%)
Consulting$18,590 (30.8%)
Food & Beverage$8,347 (13.8%)
Education$495.13 (0.8%)
Travel$84.92 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,435 | 10 | 48.8% |
| Consulting Fee | $18,590 | 20 | 30.8% |
| Food and Beverage | $8,347 | 321 | 13.8% |
| Honoraria | $2,425 | 2 | 4.0% |
| Long term medical supply or device loan | $931.52 | 10 | 1.5% |
| Education | $495.13 | 22 | 0.8% |
| Travel and Lodging | $84.92 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27,116 | 45 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $5,663 | 5 | $0 (2017) |
| Eli Lilly and Company | $4,375 | 1 | $0 (2022) |
| GENZYME CORPORATION | $4,225 | 20 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $3,807 | 4 | $0 (2023) |
| Karyopharm Therapeutics Inc. | $2,473 | 8 | $0 (2023) |
| BeiGene USA, Inc. | $1,950 | 1 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,440 | 38 | $0 (2024) |
| Puma Biotechnology, Inc. | $1,150 | 3 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,110 | 17 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,781 | 47 | GENZYME CORPORATION ($3,562) |
| 2023 | $3,574 | 94 | Janssen Scientific Affairs, LLC ($1,090) |
| 2022 | $7,182 | 71 | Eli Lilly and Company ($4,375) |
| 2021 | $1,794 | 37 | AstraZeneca Pharmaceuticals LP ($593.02) |
| 2020 | $2,880 | 20 | Karyopharm Therapeutics Inc. ($2,282) |
| 2019 | $12,444 | 46 | E.R. Squibb & Sons, L.L.C. ($8,943) |
| 2018 | $7,497 | 29 | E.R. Squibb & Sons, L.L.C. ($5,889) |
| 2017 | $18,156 | 44 | E.R. Squibb & Sons, L.L.C. ($11,652) |
All Payment Transactions
388 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 12/07/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | Cash or cash equivalent | $133.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $27.18 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: Oncology | ||||||
| 11/15/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $27.84 | General |
| Category: Genetically Defined Disease | ||||||
| 11/12/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: HEMATOLOGY | ||||||
| 11/05/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $33.09 | General |
| 10/31/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.52 | General |
| Category: Hematology | ||||||
| 10/29/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: Oncology | ||||||
| 10/22/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $27.10 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $31.94 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $30.24 | General |
| Category: ONCOLOGY | ||||||
| 09/17/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $29.15 | General |
| Category: Hematology/Oncology | ||||||
| 09/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $34.32 | General |
| 08/29/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: Oncology | ||||||
| 08/27/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $28.46 | General |
| Category: Oncology | ||||||
| 08/22/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Education | In-kind items and services | $16.40 | General |
| Category: ONCOLOGY | ||||||
| 08/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $3,295.00 | General |
| Category: Oncology | ||||||
| 08/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $250.00 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $28.97 | General |
| Category: BioOncology | ||||||
| 08/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | In-kind items and services | $17.37 | General |
| Category: Oncology | ||||||
| 08/12/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $32.29 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 53 | 5,613 | 49,742 | $1.9M | $754,995 |
| 2022 | 51 | 5,301 | 53,441 | $2.9M | $1.2M |
| 2021 | 45 | 4,756 | 34,834 | $2.6M | $1.1M |
| 2020 | 43 | 4,216 | 27,852 | $2.0M | $791,618 |
Total Patients
19,886
Total Services
165,869
Medicare Billing
$3.8M
Procedure Codes
192
All Medicare Procedures & Services
192 procedure records from CMS Medicare Utilization — Page 3 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 14 | 41 | $94.72 | $34.31 | 36.2% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2023 | 13 | 25 | $75.00 | $25.11 | 33.5% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 12 | 321 | $0.29 | $0.28 | 96.6% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2022 | 12 | 13,026 | $1.4M | $548,025 | 40.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 441 | 1,515 | $418,565 | $164,114 | 39.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 25 | 4,628 | $195,977 | $79,580 | 40.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 169 | 384 | $148,871 | $58,469 | 39.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 51 | 394 | $124,103 | $50,745 | 40.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 126 | 422 | $89,759 | $36,919 | 41.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 116 | 141 | $57,999 | $23,698 | 40.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 144 | 258 | $50,594 | $19,535 | 38.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 447 | 1,554 | $32,820 | $16,180 | 49.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 40 | 555 | $37,832 | $15,493 | 41.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 82 | 82 | $38,725 | $13,923 | 36.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 25 | 73 | $32,841 | $13,575 | 41.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 488 | 1,735 | $13,574 | $13,304 | 98.0% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 11 | 89 | $32,575 | $11,228 | 34.5% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2022 | 11 | 13,770 | $30,156 | $9,380 | 31.1% |
| 83735 | Magnesium level | Office | 2022 | 391 | 1,413 | $18,934 | $9,335 | 49.3% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2022 | 417 | 1,477 | $15,302 | $7,547 | 49.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 35 | 118 | $18,315 | $7,389 | 40.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 50 | 50 | $17,898 | $7,290 | 40.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 23 | 114 | $17,399 | $7,156 | 41.1% |
| 82728 | Ferritin (blood protein) level | Office | 2022 | 237 | 409 | $11,152 | $5,486 | 49.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 54 | 82 | $12,134 | $4,977 | 41.0% |
About Dr. Ashkan Lashkari, MD
Dr. Ashkan Lashkari, MD is a Hematology & Oncology healthcare provider based in West Hills, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/17/2007. The National Provider Identifier (NPI) number assigned to this provider is 1528284627.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ashkan Lashkari, MD has received a total of $60,308 in payments from pharmaceutical and medical device companies, with $6,781 received in 2024. These payments were reported across 388 transactions from 66 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($29,435).
As a Medicare-enrolled provider, Lashkari has provided services to 19,886 Medicare beneficiaries, totaling 165,869 services with total Medicare billing of $3.8M. Data is available for 4 years (2020–2023), covering 192 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location West Hills, CA
- Active Since 04/17/2007
- Last Updated 09/30/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1528284627
Products in Payments
- OPDIVO (Biological) $20,661
- EMPLICITI (Biological) $5,848
- NINLARO (Drug) $5,663
- SARCLISA (Biological) $3,965
- IMBRUVICA (Drug) $2,890
- XPOVIO (Drug) $2,473
- BRUKINSA (Drug) $1,950
- Nerlynx (Drug) $1,125
- KISQALI (Drug) $895.88
- KEYTRUDA (Biological) $420.40
- ADCETRIS (Biological) $260.25
- VERZENIO (Drug) $241.19
- ELITEK (Biological) $225.54
- TAGRISSO (Drug) $225.00
- IBRANCE (Drug) $196.05
- BESREMI (Drug) $181.99
- LIBTAYO (Biological) $172.44
- CYRAMZA (Drug) $172.26
- ENHERTU (Biological) $164.06
- TABRECTA (Drug) $152.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in West Hills
Mr. Christopher Ho, M.d, M.D
Hematology & Oncology — Payments: $79,475
Hematology & Oncology $79,475
Michael Benjamin, M.d, M.D
Hematology & Oncology — Payments: $21,070
Hematology & Oncology $21,070
Dr. Omid Shaye, M.d, M.D
Hematology & Oncology — Payments: $12,978
Hematology & Oncology $12,978
Bruce Zietz, M.d, M.D
Hematology & Oncology
Hematology & Oncology